ASX Release 23 October 2026 ASX code: PIQ National rollout of Promarker®D and Promarker®Eso to commence on 26 October 2026 Highlights • National rollout of Promarker D and Promarker Eso through Healius, Proteomics International’s exclusive Australian pathology distribution partner, scheduled...
National Rollout of PromarkerD and PromarkerEso
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has announced the national rollout of Promarker D and Promarker Eso blood tests, set to begin soon. This rollout is in collaboration with Healius Limited and follows a controlled market release in specific regions. Field sales teams have completed training, and systems are being integrated to facilitate patient blood collection and payment. The company is also preparing for the commercial release of Promarker Endo, expected in the near future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Notice of Annual General Meeting/Proxy Form
- Proteomics International receives $2.0m in R&D tax incentive
- Ignite Investment Summit Presentation
- PromarkerEndo Validation and Refinement Complete
- Notice of AGM Date
Later from Proteomics International Laboratories
- Quarterly Activities/Appendix 4C Cash Flow Report
- Proteomics International Launches Share Purchase Plan
- Proposed issue of securities - PIQ
- Share Purchase Plan Cleansing Notice
- Security Purchase Plan Offer Booklet
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories